Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase 11-8-22)24-6-5-20(16-35-24)26-33-12-2-13-34-26/h1-6

11-8-22)24-6-5-20(16-35-24)26-33-12-2-13-34-26/h1-6

PubMed PMID: 25966657

135897-06-2

Ledipasvir shows good half-lives (rat 1

Macdonald TL

Abiraterone - CYP17 inhibitor Abiraterone (CB-7598). CAS# 154229-19-3 one Demethylase 11-8-22)24-6-5-20(16-35-24)26-33-12-2-13-34-26/h1-6Abiraterone, CAS No. 154229 19 3, is the first in class potent and selective CYP17 (cytochrome P450 17alpha hydroxylase 17, 20 lyase) inhibitor with IC50 ~4 nM. It was approved by US FDA in 2011 to treat castration resistant prostate cancer. As prostate cancer cells proliferate in response to androgen steroids, CYP17 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic prostate cancer. In recent Nature publication,